<DOC>
	<DOCNO>NCT01971047</DOCNO>
	<brief_summary>The purpose study compare safety efficacy intravenous ( IV ) administration FDA approve regular human insulin subcutaneous ( SC ) administration humalog , rapid-acting insulin analog ( synthetic insulin ) , correction hyperglycemia ( high blood sugar ) immediate preoperative period patient diabetes outpatient surgery Emory Ambulatory Surgical Center ( ASC ) . In randomized control clinical trial patient diabetes administered corrective dos IV regular insulin SC humalog preoperative hyperglycemia determine whether SC humalog result improve intra post-operative blood sugar control.The common current practice Emory University ambulatory surgical setting IV administration regular insulin treatment pre-operative hyperglycemia . Subjects pay participation assure treatment hyperglycemia regardless study participation .</brief_summary>
	<brief_title>Safety Efficacy Study Correcting Hyperglycemia Patients With Diabetes Having Out-patient Surgery</brief_title>
	<detailed_description>Investigators plan randomize total 200 male female subject type 1 type 2 diabetes , patient surgical procedure , meet inclusion criterion receive corrective dos IV regular insulin ( Group I ) SC humalog insulin ( Group II ) . The dose formula per Emory University Outpatient Surgical Center protocol treat hyperglycemia group . All patient diabetes undergo blood sugar measurement upon arrival ASC use Accuchek blood glucose meter . An admission blood sugar &gt; 180 patient diabetes qualifies patient study screening . Subjects approach confirmation eligibility study . Randomization , treatment , occur immediately follow write informed consent . Demographic data recorded.A medical history detailed history diabetes obtain surgical anesthesia detail length stay record . Blood sugar level check hourly patient ready discharge . Subsequent treatment follow hyperglycemia protocol . All blood sugar result dose insulin record . The subject 's participation end time discharge Ambulatory Surgical Center .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Male female patient age 18 80 year type 1 type 2 diabetes patient undergo ambulatory surgery know history diabetes &gt; 3 month treat diet , oral antidiabetic agent and/or insulin therapy subject admission/randomization Blood glucose &gt; 180 &lt; 400 mg/dl Patients willing able provide inform consent Age &lt; 18 &gt; 80 Subjects increase blood glucose concentration , without history diabetes ( stress hyperglycemia ) Patients insulin pump Patients history clinically significant hepatic disease ( cirrhosis , jaundice , endstage liver disease , portal hypertension ) end stage renal disease Current recent ( within 3 month ) treatment oral injectable corticosteroid , parenteral nutrition immunosuppressive treatment Mental condition render subject unable understand nature , scope possible consequence study Female subject pregnant breastfeeding time qualify outpatient procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Surgery</keyword>
	<keyword>anesthesiology</keyword>
	<keyword>endocrinology</keyword>
</DOC>